• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin gets tentative approval from US FDA for empagliflozin tablets

expresspharmaAugust 05, 2020

Tag: lupin , empagliflozin tablets , Diabetes

Lupin has received tentative approval for its empagliflozin tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (US FDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Empagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin Tablets, 10 mg and 25 mg had an annual sales of approximately $4,368 million in the US (IQVIA MAT Mar 2020).


Previous:Kokate Committee releases list of 471 rational FDCs

Next:Manslaughter charges on Sanofi over epilepsy drug Depakine

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin gets tentative approval from US FDA for empagliflozin tablets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Miglitol 99%min Pharmaceutical Diabetes drug made in china

Miglitol 99%min Pharmaceutical Diabetes drug made in china
Refilled Diabetes insulin pen in disposable use with 3ml Cartridge in plastic materials

Refilled Diabetes insulin pen in disposable use with 3ml Cartridge in plastic materials
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts
Portable Diabetes Insulin Pen in Attractive Design

Portable Diabetes Insulin Pen in Attractive Design
Acarbose EP used for Diabetes treatment made in China

Acarbose EP used for Diabetes treatment made in China
Refillable Insulin Pen, Insulin Injection Devices For Diabetes patients self-administration

Refillable Insulin Pen, Insulin Injection Devices For Diabetes patients self-administration
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service